The Transparency Commission of the French National Authority for Health recently decided not to reimburse an Alzheimer’s drug (Lecanemab) that had been granted marketing authorisation in the European Union.

What scientific, clinical and medico-economic issues explain or challenge this decision?

To discuss  we will have presentations from experts from various backgrounds:

– Driss Berdaï (Medical Pharmacology)
– Vincent Planche (Neurologist)
– Clémence Thébaut (Health economist)

Panelists : Carole Dufouil (Epidémiology), Thibaud Haaser (Bioethics and Medical Ethics)

Open to everyone, in person

📅 Tuesday, 6 January 2026, 4:00 p.m. – 5:30 p.m.

📍 Amphi Louis – ISPED – Campus Carreire , University of Bordeaux, 146 Rue Léo Saignat, 33000 Bordeaux